Date: 2014-10-30
Type of information: Nomination
Compound:
Company: Abivax (France)
Therapeutic area: Infectious diseases - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 30, 2014, Abivax, the Paris-based clinical stage biopharmaceutical company specialised in the development and commercialisation of therapeutic vaccines and anti-viral compounds announced the appointments of Karl Birthistle, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively. These two senior appointments further strengthen the Executive Management team led by Prof. Hartmut Ehrlich, M.D., CEO of Abivax and supported by both the Board of Directors and the Company’s Scientific Advisory Board. Karl Birthistle is a physician with broad experience in a number of therapeutic areas, gained as he progressed from a Cardiology Intern in Dublin to Senior Registrar in Virology at George’s Hospital Medical School in London. After more than 10 years treating patients, Karl joined the pharmaceutical and biotech industry and held positions of increasing responsibility in drug, biologics and vaccines development and medical affairs. He has previously worked at SmithKlineBeecham (Harlow, UK), Bayer (Slough, UK), Pharming (Leiden) and Baxter BioScience (Vienna, Austria), where he was Therapeutic Area Head for Immunology and Critical Care. He went on to become Director of Clinical Development and Safety Assessments for Philip Morris (Neuchatel, Switzerland), and then joined Swissmedic (Bern, Switzerland), the regulatory authority in Switzerland, as Deputy Head, Division Clinical Review. Daniel Kenny is an accomplished biopharmaceutical business leader, with almost 30 years’ experience in the Global Pharmaceutical industry. In his career he has developed and successfully driven business with industry leaders such as Roche (strategic marketing plans for the launch of Tamiflu®) and Allergan. Prior to joining Abivax, Daniel served as Global Franchise Head at Baxter Vaccines. In this role he led a successful reinvigoration of the base commercial business, significantly exceeding the financial plan for the Franchise in each of the three years of his tenure. Before assuming this post, Daniel served as Vice President Baxter BioScience, EMEA with responsibility for all marketing and key business programmes in support of regional sales exceeding $1.9billion. Daniel completed over 10 years in clinical research in the fields of ophthalmology and HIV/AIDS prior to join the pharmaceutical industry. Daniel is a graduate in Physics from the University of New South Wales and has completed Executive business studies at both INSEAD and the London Business School. Abivax is developing a number of innovative therapeutic vaccines and antivirals, including clinical stage products ABX203 therapeutic vaccine against chronic hepatitis B and the antiviral ABX464 against HIV. The broader ABIVAX portfolio includes additional therapeutic vaccines and anti-viral compounds that may enter the clinical stage in the coming 12-18 months. Abivax utilises a technology platform leveraging RNA-protein interaction Interference, B cell and cytotoxic TH1 cell amplification to generate proprietary breakthrough therapies that are designed to help patients clear important pathogenic viruses such as HIV, HBV and HPV. The company conducts its research and development in Évry (France) and Montpellier (France). In addition, Abivax benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), the British Columbia Cancer Agency (Vancouver, Canada), the CNRS (Montpellier, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA) and the Institut Pasteur (Paris, France).
Financial terms:
Latest news:
